NantOmics

19 articles about NantOmics

• ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients

  6/28/2021

  ImmunityBio and NantOmics today announced publication of a stepwise approach or “pipeline” for identification and validation of neoepitope and neoepitope-reactive T cells from individual patients.

• NantOmics and NantHealth Announce Results of Proprietary Machine Vision AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of Breast Cancer From Digital Pathology Images

  2/19/2020

  Feb. 19, 2020 13:00 UTC Study Published In Breast Cancer Research Shows How Deep-Learning Of Over 650 Breast Cancer Digital Pathology Images And Omics Data Can Be Used Together To Unlock Precise Mechanisms Of Therapy Resistance CULVER CITY, Calif.--( BUSINESS WIRE )-- NantOmics, LLC , the leader in molecular analysis, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today the publication of a peer-reviewed stu

• NantHealth and NantOmics Reveal a Novel AI Based Machine-Learning Digital Pathology Software for Lung Cancer by Identifying Tumor Infiltrating Killer Cells From Whole Slide Images

  1/28/2020

  Derived from deep-learning models, the findings demonstrate novel AI methods of identifying tumor-infiltrating lymphocytes (TILs) in lung cancers

• NantHealth and NantOmics to Present Data on Tumor Mutation Burden (TMB) and PD-L1 Expression in SDH/FH Mutated Solid Tumors at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

  6/3/2019

  Results to be presented during the cancer prevention, hereditary genetics and epidemiology session at the ASCO 2019 Annual Meeting

• NantHealth® and NantOmics to Reveal New Research Demonstrating Importance of Examining RNA Expression and Individual Biomarkers in Cancer Testing

  2/14/2019

  Findings to be presented at the 2019 American Society of Clinical Oncology’s Genitourinary Cancers Symposium

• NANT Receives FDA Authorization for New Clinical Trials with Personalized, Next-Generation Neoepitope Cancer Vaccine

  6/3/2018

  NANT announced on June 3 that the Food and Drug Administration authorized clinical trials for the company’s investigational neoepitope yeast vaccine, YE-NEO-011, for a personalized, next-generation cancer immunotherapy.

• NantOmics to Present Results of DESMOPAZ Study from French Sarcoma Group (FSG) at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantOmics, LLC will present findings on how pazopanib (PZ) has meaningful clinical activity in patients with progressive desmoid tumors (DT) during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantOmics to Share Results of NantOmics Pharmacogenomics Test at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantOmics, LLC, will present results from the NantOmics pharmacogenomics test, an integrative panomic approach to pharmacogenomics screening, during the developmental therapeutics session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantOmics to Present Potential Treatment Options for SCLC Patients with Multiplexed Clinical Proteomic Testing at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantOmics, LLC will present findings on potential treatment options for small-cell lung cancer (SCLC) patients with multiplexed clinical proteomic testing during the lung cancer.

• NantHealth and NantOmics to Present Patterns of Immune Checkpoint Molecules in Relation to PD-L1 Expression at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantHealth, Inc., and NantOmics, LLC will present findings on how targeting immune checkpoints and employing combinations has led to clinical benefit across a variety of tumor types during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantHealth and NantOmics to Present Data on the Frequency of Non-Expressed Variants Tested by Standard NGS Panel at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantHealth, Inc. and NantOmics, LLC will present findings on how 17 percent of next generation sequencing (NGS) 50 gene panel variants are not expressed in RNA sequencing during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantOmics to Report Data on Cardiac Function in Sarcoma Patients Receiving Aldoxorubicin with Doxorubicin Equivalent Doses over 1000 mg/m2 at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantOmics, LLC will present data on cardiac function in patients treated with aldoxorubicin in combination with Doxorubicin during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

• NantOmics to Present Data for Mutational Processes and Response to Neoadjuvant Chemotherapy in Breast Cancer at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantWorks, LLC announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present findings on a genome-based investigation in the neoadjuvant GeparSepto trial for breast cancer treatment during the breast cancer session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantOmics to Present Analysis on Potential Therapeutic Target in Adenoid Cystic Carcinoma at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantWorks, LLC announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present an analysis on how comprehensive molecular profiling with proteomic and genomic analysis revealed CDK6 as a potential therapeutic target in adenoid cystic carcinoma (ACC).

• NantHealth and NantOmics to Present Data on Three-Fold Overestimation of Tumor Mutation Burden Using Gene Panel vs Whole Exome at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantHealth and NantOmics will present data on three-fold overestimation of tumor mutation burden (TMB) using a 248 gene list as a panel to impute TMB during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantWorks Release: NantOmics To Present Clinical Trial Data On The Characterization Of Molecular Profiles Of Metastatic Triple Negative Breast Cancer With GPS Cancer™ At ASCO 2017 Annual Meeting

  6/5/2017

• NantOmicsTo Present Data On Using GPS Cancer Quantitative Proteomic Analysis Of Class III B-Tubulin (TUBB3) To Predict Survival In Gastric Cancer Patients Randomized To Docetaxel At ASCO 2017 Annual Meeting

  6/5/2017

• NantOmics To Present Data On Using GPS Cancer Proteomic Analysis To Inform Metastatic Colorectal Cancer Patient Treatment With Temozolomide At ASCO 2017 Annual Meeting

  6/5/2017

• NantOmics Acquires Genos To Bolster Its Precision Medicine Platform

  4/14/2017